HRnetGroup Limited - Record breaker

19 Aug 2021
  • Record gross profit and NPAT. Revenue increased 30.8% YoY on the back of higher permanent-recruitment rates and flexible-staffing volume. 1H21 gross profit in line at 51% of our FY21e forecast. NPAT surpassed at 75% with gains from disposal of financial assets and lower SG&A.
  • Flexible-staffing growth likely to continue amid business uncertainties. Permanent-recruitment volume to pick up with countries’ reopening.
  • Maintain BUY with a higher TP of S$1.05 from S$1.00. After adjusting for one-off items, our FY21e core PATMI increases by 8.8% as we lift flexible-staffing revenue and lower SG&A expenses. Our TP remains pegged to 14x FY21e ex-cash P/E, HRnet’s historical 5-year high as we anticipate labour market recovery and potential M&As.

The Positives

+ Record gross profit and NPAT. 1H21 revenue and gross profit were in line at 54%/51%, but NPAT and PATMI exceeded at 75% of our estimates. We attribute this to S$6.8mn of net fair value gains from its disposal of financial assets and lower-than-expected SG&A expenses. Permanent-staffing revenue grew 25.1%, underpinned by a 17.5% increase in revenue per placement YoY as HRnet filled more senior and niche positions that command higher remuneration packages. Flexible-staffing revenue rose by 31.9% on the back of a 47.1% YoY spike in the number of contractors hired to an all-time-high of 17,123 in June 2021. This was thanks to its Recruit First business expansion in 2019 and 2020 and clients’ preference for manpower flexibility amid business uncertainties.   


+ Recovery in key markets. Singapore is HRnet’s largest revenue and gross-profit contributor. 1H21 gross profit in this market grew 31.1% YoY: flexible staffing +33.5% and permanent recruitment +25.0%. Gross profit in North Asia, comprising China, Hong Kong and Taiwan, was up 29.9% YoY: flexible staffing +57.6% and permanent recruitment +23.9%. Volume growth was notably strong for flexible staffing in Rest of Asia, particularly Malaysia and Indonesia, where gross profit surged 40.8%.

+ Strong hiring in healthcare sector. The healthcare and life-science sector which serves pharmaceutical firms, hospitals and vaccination centres contributed 26% to revenue in 1H21, up from 15% in 1H20. The hiring of vaccination nurses constituted about 2% of revenue. Although more than 70% of the Singapore population is now fully vaccinated, demand for medical staff is still expected to come through in various forms, such as more nurses in hospitals, social-distancing ambassadors and temperature scanners at the airport. As Singapore gradually reopens borders for vaccinated travellers and a third booster shot for better immunity is within sights, hiring in the healthcare sector is not expected to pull back in the near term.


The Negative

– Pandemic-related relief tapered off. Pandemic-related assistance dropped in 1H21, as government grants and subsidies declined S$1.7mn from S$7.9mn in 1H20. We expect pandemic-related assistance to diminish by end-FY21, leaving S$4-5mn of government grants from the Wage Credit Scheme. We believe that this scheme will continue to support HRnet’s bottom line, given that the scheme has been introduced and extended since 2013.



As various Asian economies commence their recovery with the aid of vaccination programmes, pent-up demand from 2020’s hiring standstill is expected to unleash job openings and employment churns. Strong local employment is predicated on restricted border movements. Still a market leader in Singapore in revenue and profits, we remain optimistic that HRnet will be able to ride the rush for employment. While a continued recovery in the permanent recruitment of mid-level positions is contingent on a re-opening of the economies that HRnet operates in, flexible-staffing volume is expected to grow further as various sectors and organisations choose this option to avoid committing to permanent headcounts.


Maintain BUY with a higher TP of $1.05 from S$1.00.

We lift our FY21e revenue and gross profits by 1.8% and 1.1% on the back of higher-than-expected flexible-staffing contributions. FY21e NPAT and PATMI have been raised by 27.7%, after accounting for higher other income of S$10.4mn and lower SG&A expenses. The increase in other income comprises S$6.8mn of net fair value gains from its disposal of financial assets as well as an additional S$3.6mn of pandemic-related government grants.


After adjusting for the one-offs, our FY21e core PATMI increases by 8.8%. Accordingly, our TP climbs to S$1.05 from S$1.00.  This is still set at 14x FY21e ex-cash P/E, HRnet’s historical 5-year high as we anticipate labour market recovery and potential M&As.

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you


This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  


Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066